Laurion Capital Management’s Nektar Therapeutics NKTR Stock Holding History

Laurion Capital Management’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-5,650	Closed	-$48.7K	–	614
2023 Q2	$48.7K	Buy	+5,650	New	+$60.2K	﹤0.01%	566
2022 Q2	–	Sell	-6,667	Closed	-$539K	–	637
2022 Q1	$539K	Buy	+6,667	New	+$987K	0.01%	297
2020 Q3	–	Sell	-693	Closed	-$241K	–	1055
2020 Q2	$241K	Buy	+693	New	+$216K	﹤0.01%	754
2019 Q1	–	Sell	-624	Closed	-$308K	–	1156
2018 Q4	$308K	Buy	624 +385	+161%	+$232K	0.01%	817
2018 Q3	$219K	Buy	+239	New	+$204K	﹤0.01%	1013
2016 Q2	–	Sell	-1,440	Closed	-$297K	–	954
2016 Q1	$297K	Buy	+1,440	New	+$277K	﹤0.01%	597

Other funds holding NKTR

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

MAM

Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return

Laurion Capital Management's NKTR Position: Q3 2023 in Review

Laurion Capital Management sold out of Nektar Therapeutics (NKTR) in Q3 2023, closing a stake of 5,650 shares — an estimated $48.7K sold.

Laurion Capital Management first reported a position in NKTR in Q1 2016 and held it in 6 quarters. The position peaked at $539K in Q1 2022. 138 funds tracked by Wall St. Rank hold NKTR as of Q3 2023.

Laurion Capital Management reported no remaining Nektar Therapeutics position as of Q3 2023 after selling out during the quarter.
Laurion Capital Management sold 5,650 Nektar Therapeutics shares in Q3 2023, an estimated $48.7K.
Laurion Capital Management first reported a position in Nektar Therapeutics in Q1 2016 and held it in 6 quarters.
Laurion Capital Management's Nektar Therapeutics position peaked at $539K in Q1 2022.
138 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2023.

Based on Laurion Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.